Rapport Therapeutics, Inc./$RAPP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Rapport Therapeutics, Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
- Ticker
- $RAPP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 84
- Headquarters
- Boston, United States
- Website
- www.rapportrx.com
RAPP Metrics
BasicAdvanced
$1.4B
-
-$3.05
1.03
-
Price and volume
Market cap
$1.4B
Beta
1.03
52-week high
$52.93
52-week low
$23.75
Average daily volume
414K
Financial strength
Current ratio
15.721
Quick ratio
15.352
Long term debt to equity
0.018
Total debt to equity
0.024
Profitability
EBITDA (TTM)
-152.556
Gross margin (TTM)
-109.39%
Net profit margin (TTM)
-685.80%
Operating margin (TTM)
-767.58%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-25.78%
Return on equity (TTM)
-39.96%
Valuation
Price to revenue (TTM)
67.739
Price to book
3.42
Price to tangible book (TTM)
3.42
Price to free cash flow (TTM)
-13.945
Free cash flow yield (TTM)
-7.17%
Free cash flow per share (TTM)
-2.162
Growth
Earnings per share change (TTM)
21.80%
What the Analysts think about RAPP
Analyst ratings (Buy, Hold, Sell) for Rapport Therapeutics, Inc. stock.
Analyst projections of the future price of Rapport Therapeutics, Inc. stock.
Bulls say / Bears say
RAP-219 showed sustained activity after treatment stopped in a 30-patient Phase 2a focal-seizure study, with median clinical-seizure reductions of 90% in weeks 9–12 and 59% in weeks 13–16. Rapport has now moved the programme into the pivotal FOCUS 1 and FOCUS 2 Phase 3 trials. (Rapport Therapeutics, Rapport Therapeutics)
RAP-219 offers several potential value drivers beyond focal seizures: bipolar-mania Phase 2 results are due in October, a primary generalised tonic-clonic seizure Phase 3 trial is planned for the first half of 2027, and a long-acting injectable is being developed. This gives investors more than one route to clinical and commercial validation. (Rapport Therapeutics, EarningsCalls)
Rapport ended the second quarter with $436.1 million in cash, cash equivalents and short-term investments, which management expects to fund operations into the second half of 2029. That should let it run the pivotal seizure programme and pursue upcoming catalysts without an immediate funding requirement. (Rapport Therapeutics, SEC filing)
The strongest seizure evidence still comes from a small Phase 2a dataset of 30 patients, while the pivotal FOCUS 2 study is only recruiting and is not scheduled for primary completion until July 2029. The key efficacy claim therefore remains unconfirmed by a controlled Phase 3 outcome. (Rapport Therapeutics, ClinicalTrials.gov)
The company is still loss-making and its latest filing says it will need additional financing over time, even though current cash is expected to last into the second half of 2029. If trials take longer, costs rise or results disappoint, a future equity raise could dilute existing shareholders. (SEC filing, Rapport Therapeutics)
Long-term safety is not yet established at scale: the focal-seizure Phase 2a study enrolled only 30 patients, and initial data from the open-label long-term safety trial are not expected until the fourth quarter. The drug’s prolonged exposure makes that safety readout particularly important before investors can treat the early efficacy signal as durable and broadly usable. (Rapport Therapeutics, Rapport Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
RAPP Financial Performance
Revenues and expenses
RAPP Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing RAPP
AllUSDGBPEUR
Fund name | Fund size | $RAPP weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.10% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.10% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.